2型糖尿病患者的炎症和氧化应激标志物 患有晚期冠状动脉样硬化症的2型糖尿病患者
Louise Ménégaut1,2,3,4, Aline Laubriet5, Valentin Crespy5
1Université Bourgogne, LNC UMR1231, Dijon, France.
Cardiovascular diabetology
|September 14, 2023
概括
2型糖尿病 (T2DM) 与动脉样硬化有关. 马斯卡迪研究发现,在糖尿病斑块中富含2-阿拉基多尼尔-溶酸胆 (2-AA-LPC),与局部炎症相关,而不是系统性标志物.
科学领域:
- 心血管研究研究心血管研究
- 代谢障碍 代谢障碍 代谢障碍
- 分子生物学分子生物学
背景情况:
- 2型糖尿病 (T2DM) 是全球主要的健康问题,也是动脉样硬化的重要危险因素.
- 糖尿病动脉样硬化症的特点是炎症,胰岛素抵抗,高血糖症,脂质失调症和氧化应激.
- 了解T2DM中的动脉硬性斑块的分子特征对于了解疾病发病过程至关重要.
研究的目的:
- 调查T2DM患者心动脉斑块中2-阿拉基多-溶酸胆 (2-AA-LPC) 的增加.
- 探索2-AA-LPC与斑块脆弱性和糖尿病中改变生物标志物的关联.
- 阐明阿拉基酸代谢在糖尿病动脉样硬化中的作用.
主要方法:
- 在MASCADI研究中,分析了T2DM和对照患者的状动脉斑块.
- 测量了2-AA-LPC和各种系统性和斑块内生物标志物的水平.
- 与临床数据,炎症标志物和斑块特征相关的2-AA-LPC水平.
主要成果:
- 与对照组相比,T2DM患者表现出较高的全身炎症标志物 (hsCRP,IL-1β),氧醇,甘油三和较低的HDL.
- 在糖尿病患者的动脉样硬化斑块中,2-AA-LPC被显著丰富.
- 2-AA-LPC与斑块内炎症标志物 (lysophospholipids,25-hydroxycholesterol) 相相关,但没有系统性糖尿病标志物.
结论:
- 炎症在糖尿病动脉样硬化的发病过程中起着关键作用.
- 2-阿拉基多诺伊尔-溶酸胆 (2-AA-LPC) 与糖尿病动脉样硬化有关.
- 需要进一步的研究来了解局部斑块过程,并确定T2DM的治疗点.
相关概念视频
01:30Coronary Artery Disease I: Introduction
20
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
01:30Atherosclerosis I: Introduction
9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
13
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
13
01:19Psychoneuroimmunology: Diabetes and Cancer
47
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
47
01:26Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12